This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals

This study has been completed.
Information provided by:
Regional Hospital Holstebro Identifier:
First received: April 5, 2006
Last updated: February 17, 2010
Last verified: February 2010
We, the investigators at Holstebro Hospital, want to test the hypothesis that dihydralazine leads to the activation of the sympathetic nervous system in healthy individuals.

Condition Intervention Phase
Healthy Drug: Dihydralazine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Official Title: The Effect of Dihydralazine on Renal Tubular Function and Vasoactive Hormones in Healthy Individuals

Resource links provided by NLM:

Further study details as provided by Regional Hospital Holstebro:

Primary Outcome Measures:
  • Fractional sodium excretion
  • Heart rate
  • Blood pressure

Estimated Enrollment: 16
Study Start Date: April 2006
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Men
  2. Ages 18 to 40 years.
  3. Body mass index less than or equal to 30 kg/m2

Exclusion Criteria:

  1. History or clinical signs of heart, lung, kidney, or endocrine organ disease.
  2. Abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine, P-albumin, P-bilirubin, P-alanine aminotransferase, P-alkaline phosphatase, P-cholesterol, and B-glucose.
  3. Abnormal screening of the urine regarding: albumin and glucose
  4. Malignant disease.
  5. Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg systolic or 85 mmHg diastolic.
  6. Alcohol abuse.
  7. Smoking.
  8. Drug use or abuse.
  9. Known intolerance or allergy to dihydralazine
  10. Blood donation within 1 month of the start of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00311974

Department of Medical Research, Holstebro Hospital
Holstebro, Denmark, 7500
Sponsors and Collaborators
Regional Hospital Holstebro
Study Chair: Erling B Pedersen, Professor Department of Medical Research, Holstebro Hospital, Denmark
Principal Investigator: Henrik Vase, MD Department of Medical Research, Holstebro Hospital, Denmark
  More Information Identifier: NCT00311974     History of Changes
Other Study ID Numbers: MED.RES.HOS.2006.01.HV
Study First Received: April 5, 2006
Last Updated: February 17, 2010

Keywords provided by Regional Hospital Holstebro:
Sympathetic activation
Fractional sodium excretion

Additional relevant MeSH terms:
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antihypertensive Agents processed this record on September 21, 2017